Biomarkers and Photodynamic Therapy for Barrett's Esophagus: Time to FISH or Cut Bait?

Gastroenterology

Volumn 135, Issue 2, 2008, Pages 354-357

  Spechler, Stuart Jon ^a   Souza, Rhonda F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

APOPTOSIS; BARRETT ESOPHAGUS; CARCINOGENESIS; CLINICAL TRIAL; DNA DAMAGE; EDITORIAL; ENDOSCOPIC THERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; GENETICS; HUMAN; MUTATION; OXIDATIVE STRESS; PATIENT SAFETY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT OUTCOME;

EID: 48549090849     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.06.065     Document Type: Editorial

References (12)

1. Feagins L.A., and Souza R.F. Molecular targets for treatment of Barrett's esophagus. Dis Esophagus 18 (2005) 75-86
2. Gatenby R.A., and Vincent T.L. An evolutionary model of carcinogenesis. Cancer Res 63 (2003) 6212-6220
3. Spechler S.J. Dysplasia in Barrett's esophagus: limitations of current management strategies. Am J Gastroenterol 100 (2005) 927-935
4. Sharma P., Falk G.W., Weston A.P., et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 4 (2006) 566-572
5. Piette J., Volanti C., Vantieghem A., et al. Cell death and growth arrest in response to photodynamic therapy with membrane-bound photosensitizers. Biochem Pharmacol 66 (2003) 1651-1659
6. Overholt B.F., Wang K.K., Burdick J.S., et al., International Photodynamic Group for High-Grade Dysplasia in Barrett's Esophagus. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 66 (2007) 460-468
7. Prasad G.A., Wang K.K., Halling K.C., et al. Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology 135 (2008) 370-379
8. Wong D.J., Paulson T.G., Prevo L.J., et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 61 (2001) 8284-8289
9. Sherr C.J. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6 (2006) 663-673
10. Feagins L.A., Zhang H.Y., Hormi-Carver K., et al. Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells. Am J Gastroenterol 102 (2007) 10-20
11. Crescenzi E., Chiaviello A., Canti G., et al. Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299). Mol Cancer Ther 5 (2006) 776-785
12. Shaheen N.J., Sharma P., Overholt B.F., et al. A randomized, multicenter, sham-controlled trial of radiofrequency ablation for subjects with Barrett's esophagus containing dysplasia: interim results of the Aim dysplasia trial. Gastroenterology 134 suppl 1 (2008) A37